Rockwell Medical (NASDAQ:RMTI) released its earnings results on Friday. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05, MarketWatch Earnings reports. The business had revenue of $16.67 million during the quarter, compared to analysts’ expectations of $15.00 million. Rockwell Medical had a negative net margin of 55.38% and a negative return on equity of 89.63%.
NASDAQ RMTI traded up $0.79 during trading hours on Friday, hitting $4.38. 485,859 shares of the company’s stock traded hands, compared to its average volume of 151,407. Rockwell Medical has a 52-week low of $3.55 and a 52-week high of $6.98. The stock has a market cap of $198.54 million, a PE ratio of -8.59 and a beta of 1.42.
A number of analysts have recently commented on the stock. Zacks Investment Research raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Friday. Ifs Securities reissued an “outperform” rating and set a $11.00 target price on shares of Rockwell Medical in a research note on Friday, October 19th. Finally, ValuEngine raised shares of Rockwell Medical from a “hold” rating to a “buy” rating in a research note on Tuesday, September 4th.
COPYRIGHT VIOLATION NOTICE: “Rockwell Medical (RMTI) Releases Earnings Results, Beats Expectations By $0.05 EPS” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2018/11/10/rockwell-medical-rmti-releases-earnings-results-beats-expectations-by-0-05-eps.html.
Rockwell Medical Company Profile
Rockwell Medical, Inc operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment.
Read More: Determine Your Level of Risk Tolerance
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.